All News

Systematic review of DYSPHAGIA in inflammatory myositis finds it may be an initial or sole symptom. Prevalence in IIM was 36% and higher 56% inclusion body myositis, cancer or NXP2 -associated myositis. Dysphagia may be complicated by aspiration pneumonia https://t.co/wDg3tWaooP

Links:

Dr. John Cush RheumNow ( View Tweet)

The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets https://t.co/IWbiVw9PSP

Links:

Victoria Shanmugam VickiShanmugam ( View Tweet)

Italian report of 2 cases (1 w/ stable RA;1 without prior arthritis) who developed polyarthritis after hospitalization for COVID pneumonia. Synovial Bx showed synovial proliferation - 1 w/ crystals and both w/ CD3+ and CD138+ cells https://t.co/ZRRrWIjZXg

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology reports a UK study of Clinical Practice Research Datalink and 17 760 incident RA pts; 42% who recv steroids; The HTN rate was 64.1 per 1000 PY & GC use assoc w/ 17% increased risk HTN (hazard ratio 1.17), esp at doses > 7.5 mg/d https://t.co/31Q2xiwvMp

Links:

Dr. John Cush RheumNow ( View Tweet)

Canadian 1484 incident early #RA pts (enrolled 2007–2017). SC MTX monotherapy had fewer Rx changes(45% SC vs 79% PO)with longer treatment duration. Similarly taking biologics or triple therapy had a longer time without treatment change. https://t.co/babj1MvTNB

Links:

Dr. John Cush RheumNow ( View Tweet)

RA9003.jpg (keep)

JAK Inhibitor Succeeds as Monotherapy in Rheumatoid Arthritis

d RheumNow

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.

Read Article
NEW #COVID19—"Symmetric peripheral polyarthritis developed during #SARSCoV2 infection" Comment by Rosario Talarico and colleagues https://t.co/IqHp2GMLao #LancetRheumatology https://t.co/v3MBNDUnzG

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)

FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis. https://t.co/zMNsDjVewU

Links:

Dr. John Cush RheumNow ( View Tweet)

Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM

Links:

Dr. John Cush RheumNow ( View Tweet)
Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM

Links:

Dr. John Cush RheumNow ( View Tweet)
H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in P… https://t.co/7lwVCSYjPu

Links:

Dr. John Cush RheumNow ( View Tweet)

Plaquenil.HCQ_.pills_.jpg (keep)

ICYMI: The Nine Lives of Hydroxychloroquine (Updated)

d Martin J. Bergman, MD

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.

Read Article
Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Links:

Dr. John Cush RheumNow ( View Tweet)

Case Controlled Study of 482 RA patients with ILD vs 741 RA w/o IL found an inverse relationship Between MTX exposu… https://t.co/ljtaKO8pVZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatologist Question: early on, what do you tell your RA patient their chance of future drug free remission?

Dr. John Cush RheumNow ( View Tweet)

Rheumatoid Arthritis: Pathogenesis, Prediction and Prevention – An Emerging Paradigm Shift https://t.co/uNDsLmgaN7 #RA #prevention #Rituximab - nice article, still think if repeated Ritux to eliminate pathogenic abs would significantly prevent RA

Links:

Peter Nash drpnash ( View Tweet)

Claims data study of nearly 3 million receiving influenza vaccination shows an increased risk of subsequent subdeltoid bursitis, but incredibly low with an attributable risk was 7.78 additional bursitis per 1 million vaccinated.https://t.co/qtzd8pWk4O

Links:

Dr. John Cush RheumNow ( View Tweet)

Pneumonia vaccination of 21461 RA pts in UK Clinical Practice Research Datalink (2000-18) finds 38.2% vaccinated; 44.3% ≥65 years, 66.4% female; 36.5% vaccinated prior to starting csDMARDs, moreso in elderly. VAX increased over time (esp 2003 to 2007) https://t.co/QTedUMWvE0

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.